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Abstract

Biological variability (BV) has important applications in laboratory medicine. It can be a
source of variation in measured analyte values and provide guidance on reference
interval use. BV has three components: between-individual variation (CVg), caused by
differences in mean values of a particular analyte among members of a group, withinindividual variation (CVi), caused by fluctuations around an individual’s inherent
homeostatic set point, and analytical variation (CVa). Thromboelastography (TEG), a
type of viscoelastic coagulation analysis, is becoming increasingly common in veterinary
referral centers. Despite increased popularity, the optimal method of results
interpretation is not clear. While population-based reference intervals (PRI) are used for
many analytes, reference change values (RCV) are more sensitive for disease detection
for other analytes. The relative sensitivity of PRI or RCV in detecting significant
deviations of reported analyte values can be derived from BV data, via incorporation of
CVi and CVg into a simple formula to calculate index of individuality (IOI). This study
measured BV of four TEG variables R, K, angle and MA in clinically healthy horses and,
using calculated IOI, found that population-based reference intervals are appropriate
when interpreting results from individual animals. Additionally, the ability to freeze a key
reagent used in the TEG assay, tissue factor, was also investigated.
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Chapter 1: Introduction

Variation is inherent to all laboratory measurements. Even repeated measurements
from one animal of unchanged health status, performed in the same laboratory using
the same analytical methods, will often result in slightly different reported values.
Causes of this variation include pre-analytical and analytical factors, such as differences
in patient preparation, sample acquisition and handling, and instrument calibration. An
additional source of variation, not often considered in veterinary medicine, is biological
variation (BV). BV of a given analyte is assessed by measuring within-individual
variation (CVi) and between-individual variation (CVg). CVi is caused by natural
fluctuations in an analyte’s concentration or activity relative to an individual’s
homeostatic set-point. CVg occurs between members of a group, all of whom have
their own unique homeostatic set-points caused by differences in genetic makeup,
environmental factors, and health status.1
Although population-based reference intervals (PRI) are often used to interpret
laboratory data, a reference change value (RCV) may be a more sensitive means to
detect medically significant deviations from “normal” for some analytes. 2 A PRI, by
convention, encompasses values from the central 95% of a reference sample
population and defines an upper and lower reference limit. Patient results falling
outside of these limits are considered “abnormal” and are likely of medical significance.2
As CVg increases relative to CVi, the central 95% of data also increases due to the
wider range of measured values in the reference population. It is possible for a PRI to
be so wide that medically significant deviations from an individual’s set point will still fall
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within the normal reference interval, rendering the PRI insensitive for disease detection.
For these analytes, calculating reference change value (a.k.a. critical difference or
subject-based reference values) will likely be of benefit. RCV defines the difference
between two serial measurements from one individual that must be achieved for a
change to be considered biologically significant, even if both results fall within a PRI.
Recent papers describing biological variation in a healthy dog population and a reptile
population concluded that results from most routine biochemical analytes and many
coagulation tests are optimally interpreted using RCV, not population-based reference
intervals.3,4,5
The index of individuality (IOI) is a standard formula that generates a unitless value
used to predict the need for PRI or RCV based on CVg and CVi.6 When IOI for a
particular analyte is over 1.4, population-based reference intervals are considered a
sensitive means by which to interpret analyte data from individual animals. When IOI is
less than 0.6, reference change values are the more sensitive means to identify
changes. In order to apply BV to clinical interpretation of laboratory data, analytical
variation (CVa) must also be known. If CVa is very high, medically important changes
may become obscured in the wide range of values inherent to the particular analytical
method. Additionally, analytical variation is incorporated into the IOI formula and very
large CVa values may impact calculated IOI.6
Viscoelastic coagulation analyzers are becoming increasingly common in veterinary
tertiary referral centers, creating availability of these assays for some horse populations.
Four commonly reported thromboelastography variables include the time to initial fibrin
formation (R), kinetics of fibrin formation and clot development (K and angle,
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respectively), and maximal clot strength (MA).7 A BV study on these TEG variables in
dogs using a tissue factor-activated assay and frozen plasma, revealed a relatively
small CVg and large CVi, suggesting that PRIs are appropriate for clinical interpretation
of patient data.5 In contrast, a recent study in horses identified overlap of TEG data
from healthy horses and horses with gastrointestinal disease; the extent to which BV
may have contributed to these findings is not known.8
The main objective of this thesis work was to characterize biological variation
(expressed as CVi and CVg) and analytical variation (CVa) of four TEG variables (R, K,
angle and MA) in clinically healthy horses and to determine if use of population-based
reference intervals is appropriate for clinical interpretation.
Before completing the biological variation study, investigation into the stability of a
key reagent, Innovin (Dade-Behring, Marburg, Germany), was performed. Innovin is a
lyophilized reagent containing human recombinant tissue factor (TF), synthetic
phospholipids, calcium and a mix of other stabilizers and buffers marketed for
prothrombin time assay.9 Innovin has also been used to activate viscoelastic
coagulation assays, including TEG assays.10,11,12 Benefits of TF-activated assays
include faster reaction times and possibly improved precision and decreased intraoperator variability.11,12,13 Although anecdotal reports suggest that freezing does not
harm Innovin’s activity for purposes of TEG (CR Wagg, DACVP, e-mail
correspondence, July 15, 2011; RC Carroll, PhD, e-mail correspondence, April 12,
2013), the package insert warns it should not be frozen. The ability to prepare aliquots
and store TF prior to use would increase laboratory efficiency and potentially decrease
costs associated with its use, but published data regarding the effects of freezing on TF
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are not available. The purpose of the first part of the thesis work was to determine if TF
could be frozen for extended periods of time without loss of activity, as assessed by
activation of a quality control material (Level II Control, Haemoscope, Niles, IL) and
TEG.
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Chapter II

Effects of Freezing on Tissue Factor Activity in a Thromboelastography Assay
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This chapter is based on a paper by Jennifer L. Scruggs, Bente Flatland and Ann
Reed: Scruggs JL, Flatland B, Reed A. Effects of freezing on tissue factor activity in a
thromboelastography assay. Vet Clin Pathol. 2014; In press.
My primary contributions include (i) partial development of experimental design (ii)
collecting data (iii) suggestions on statistical approach, (iv) interpretation of data and (v)
the majority of the writing.

Abstract
Human recombinant tissue factor (TF) can be used to activate viscoelastic
coagulation assays, including TEG. Although the package insert of a commonly used
product indicates that TF should not be frozen, published data supporting or refuting this
claim are not available. Ability to store frozen aliquots of TF would increase laboratory
efficiency and decrease costs associated with performing TF-activated assays. The
objectives of this study were to determine the effects of freezing and storage time on
TF’s ability to activate commercially available quality control material measured using
TEG. In order to accomplish this, TF was diluted and frozen at -20°C and -70°C for 0
hours, 72 hours, 1 week, 2 weeks, 3 months and 6 months and its ability to activate
control material was assessed. TF activation of control material was also assessed
after TF aliquots were held at room temperature for 0, 24 and 48 hours. Four TEG
variables, R, K, alpha and MA were measured, and ANOVA used to identify differences.
We found no significant differences in mean angle and MA regardless of storage time or
temperature. While mean values for R were not significantly increased at any time point
when stored at room temperature or -70°C, significant increases in mean R were
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observed for aliquots frozen at -20°C starting at the 1 week time point and continuing to
the 6 months’ time point. The data indicate TF can be stored at room temperature for at
least 48 hours, stored at -20°C for 72 hours, and stored at -70°C for up to six months
without significant loss of activity.

Introduction
Quality control material II, (QCM II) is the abnormal quality control material that
mimics hypocoagulability and is used .as part of a routine, daily protocol to assess TEG
analytical performance. QCM II rather than whole blood was used in this particular
study because of two perceived advantages. First, QCM II components in a given lot
are expected to be constant. In contrast, whole blood samples (even from the same
individual) could be affected by biological variation, health status, hematocrit, sample
handling, and other pre-analytical factors known to cause variation in TEG results.1,2
The increased sample stability of QCM II made it more likely that we could isolate and
identify effects of freezing while minimizing variation attributable to other sources.
Second, use of QCM II also simplified experimental design. The timing of assays was
flexible, since QCM II could be prepared at any time, and animal use was precluded.
The objectives of this study were to determine the effects of freezing and storage time
on TF’s ability to activate commercially available quality control material (QCM II)
measured using thromboelastography.

Information from Haemonetics personnel

indicated that QCM II can be activated (Elaine Haney, MT, email communication,
September 26, 2011) and this ability was verified prior to assessment of freezing on TF.
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Materials and Methods
A pilot study demonstrated that TF could only activate QCM II when prepared by
adding 2.0 mL sterile, deionized water to a 10.0 mL vial of lyophilized Innovin (Figure 1).
TEG variables from QCM II samples with and without added TF were compared by
using a single sample t-test of the hypothesis that the mean difference between pairs,
on average, would be 0. The normality assumption was met. Since four t-tests were
performed, a Bonferroni corrected significance value of 0.0125 was used.
Accordingly, a 10 mL vial of TF was diluted using 2.0 mL sterile, deionized water,
and aliquots of diluted TF were frozen at -70°C and -20°C or maintained at room
temperature (21°C) until use. Innovin aliquots were removed from the freezer after 72
hours, 1 week, 2 weeks, 1 month, 3 months and 6 months, allowed to thaw and reach
room temperature, and then used to activate QCM II. The Innovin aliquots stored at
room temperature were used immediately (0 hours) and after being stored, in a drawer
away from light, for 24 and 48 hours.
For each TEG assay, 20 uL 0.2 M Calcium Chloride and 10 uL TF (i.e., diluted
Innovin) were added to the reaction well first, followed by 330 uL of QCM II. Weight of
material in the Innovin vial is considered proprietary information, and the exact TF
dilution achieved by reconstituting the 10 mL Innovin vial using 2.0 mL water could not
be calculated. If the dilution used is considered 1:2 (w/v), then the final dilution of TF in
the sample cup was 1:72. Temperature of the reaction well was
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Figure 1: Tissue factor activates quality control material II. Bar graphs demonstrate
that adding tissue factor (TF) to quality control material II (QCM II) significantly
decreases R and K (p < 0.0001, for both; see A and B, respectively) and significantly
increases angle (α; p < 0.0001; see C) but has no effect on MA (see D). The label,
QCM II, represents values obtained using quality control material alone, while bars
labeled TF-QCM II represent values obtained by adding TF to QCM II.
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C.

D.

Figure 1. Continued.
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was allowed to reach 37°C prior to adding any reagents and was maintained at 37°C for
the duration of the assay. Assays were allowed to run until MA was finalized. Machine
balance and e-test were assessed daily prior to sample analysis, according to
manufacturer instructions. Additionally, TEG analytical performance was monitored
daily prior to sample analysis, using two-level (normal and abnormal) quality control
materials (Level I Control and Level II Control, respectively, Haemoscope, Niles, IL) run
in duplicate. All QCM used in this study, both as daily control and experimental
samples, were prepared according to manufacturer’s instruction and were of the same
lot. Control data were considered acceptable if results fell within manufacturer-provided
ranges for each control material. All data were collected electronically using instrument
software (TEG Analytical Software Version 4.2, Haemonetics Corporation, Braintree,
MA). Each TEG assay was completed by one operator (JLS) and performed in
replicate; the average of the replicates was used for statistical analysis.

Statistical Analysis
Statistical analysis was performed using SAS/Stat software (SAS Institute Inc.,
Version 9.3 SAS for Windows, Cary, NC, 2010). ANOVA was used for means
comparisons. Values of p < 0.05 were considered significant. A Bonferroni adjustment
for multiple comparisons was used when appropriate. When significant effects were
found, means were separated by use of the least significant difference test. The
Shapiro-Wilk statistic was used to test normality of residuals from each ANOVA. The
assumption of equal variances was tested using the Levene’s F test. Since assumptions
were not adequately met, rank transformed data were used in all reported analyses.
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Results
For Innovin aliquots stored at room temperature for 0, 24 and 48 hours, no
significant differences were found in mean R, angle, or MA (p = 0.65, p = 0.81 and p =
0.68, respectively; data not shown). The mean value for K was the same at all time
points, precluding analysis. For Innovin aliquots stored at -20°C and -70°C and freshly
reconstituted Innovin (room temperature, 0 hours), effects of time and temperature were
assessed for R, angle and MA. Values for K were the same at all time and temperature
combinations and not analyzed further. There were no significant differences in mean
angle and mean MA regardless of storage time or temperature (p = 0.43 and p = 0.067,
respectively; Figure 2). There was a significant interaction of time and temperature for R
(p < 0.0001; Figure 2). While mean values for R were not significantly increased at any
time point when stored at -70°C, significant increases in mean R were observed for
aliquots frozen at -20°C starting at the 1 week time point and continuing to the 6
months’ time point (p < 0.05). Mean R obtained using freshly reconstituted Innovin
(room temperature, 0 hours) did not differ significantly from means obtained when
Innovin was stored at -20°C for 72 hours.
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Figure 2: Freezing effects tissue factor’s ability to activate quality control material II.
Line graphs demonstrating effects of freezing at two different temperatures on tissue
factor’s (TF) ability to activate quality control material II. A significant time by
temperature interaction was found for R when TF was stored at -20°C (p < 0.0001; see
A); R times increased starting at the 1 week (1 w) time point and continuing through the
six month (6m) time point. A significant time by temperature interaction was not found
for angle (α; p = 0.43; see B) or MA (p = 0.07; see C). The 0h time point reflects values
obtained from using fresh, never frozen, TF. The other time points reflect length of time
TF was frozen (h = hours, w = weeks, m = months).
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Figure 2. Continued
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Interpretation
Diluted Innovin can be frozen at -70°C for up to 6 months without significant loss of
activity and at -20°C for up to 72 hours without significant loss of activity. Consistent
with information in the Innovin package insert indicating that reconstituted TF is stable
up to five days at temperatures between 15° and 25°C, we observed TF can be stored
at least for 48 hours at room temperature (21°C).3

Discussion
As the matrix and composition of one lot of QCM material are expected to be
constant, any changes in tracings in our assay are presumed due to the addition of the
activator and its specific effects. The variable R is measured in minutes, reflects the
time between assay initiation and initial fibrin polymerization, and is very much
dependent on the rate of thrombin formation.4 The variable K is also measured in
minutes and is the time from R until an amplitude of 20 mm is reached on the TEG
tracing. In whole blood samples, K is dependent on factors II and VIII, fibrinogen,
platelet count and function, hematocrit and thrombin formation. 5
The TF used in this assay was much more concentrated than typically used with
whole blood TEG assays and likely rapidly initiated and maximized formation of the
tissue factor-Factor VII complex, resulting in a substantial and speedy thrombin burst.
This thrombin burst, in turn, increased kinetics of fibrin polymerization, shortening R
time in the activated QCM II assay. Freezing at -20°C presumably resulted in partial
degradation or inactivation of TF that became more pronounced the longer TF was
frozen, resulting in less initial thrombin formation and subsequent increasing R times. A
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study by Smith et al, using canine citrated whole blood, observed that the ROTEM
variable CFT (the equivalent of K) seemed less sensitive to changes in concentration
than did CT (the equivalent of R), suggesting that small changes in TF concentration
due to freezing would most likely manifest as changes in R and not K. 6 It also seems
plausible that the large TF concentration used in our study exceeded that required to
maximize K; this could explain why K values were identical for all TF aliquots,
regardless of storage time or temperature.
Although we did not observe a significant effect of freezing at -70°C, it is possible
that a small amount of TF did degrade but our assay was not sensitive enough to
identify this change. Previously reported whole blood assays use more dilute TF
concentrations than used in this study, and it is possible that small losses of TF activity
induced by freezing could impact R (and possibly other variables) in such whole blood
assays.7, 8, 9 Further studies could potentially better characterize effects of freezing TF
by investigating activity of more concentrations of TF than assessed in our study.
Ideally, such studies should involve activation of whole blood samples; however, sample
stability issues make design of such studies challenging. Based on the data presented
above, we suggest that freezing Innovin at -70°C for up to six months is possible, while
freezing at -20°C is recommended for only 72 hours or less. Accordingly, we prepared
a large batch of dilute tissue factor and froze aliquots in preparation for the second
study presented in this thesis.
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Biological variation of thromboelastography variables in ten healthy female horses
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This chapter is based on a paper by Jennifer L. Scruggs, Bente Flatland, Karen
McCormick and Ann Reed: Scruggs JL, Flatland B, McCormick K, Reed A. Biological
variation of thromboelastography values in ten clinically healthy horses. J Vet Emerg
Crit Care (under review).
My primary contributions included: (i) development of experimental design, (ii)
collection of data, (iii) analytical review and (iv) the majority of writing.

Abstract
Thromboelastography (TEG), a type of viscoelastic coagulation analysis, is
becoming increasingly common in veterinary referral centers. Despite increased
popularity, the optimal method of results interpretation is not clear. While populationbased reference intervals (PRI) are used for many analytes, reference change values
(RCV) are more sensitive for disease detection for other analytes. The relative
sensitivity of PRI or RCV in detecting significant deviations of reported analyte values
can be derived from BV data, via incorporation of CVi and CVg into a simple formula to
calculate index of individuality (IOI). Analytical variation is also incorporated into this
formula. BV of four TEG parameters R, K, angle and MA were measured in ten
clinically healthy horses, and within- and between-horse biological variation (CVi and
CVg, respectively) and analytical variation (CVa) were calculated using a nested
ANOVA after removing outlier data. Index of individuality was then calculated. Results
indicate that population-based reference intervals are appropriate for TEG variables R,
angle and MA when interpreting results from individual horses. Population-based
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reference intervals are likely appropriate when interpreting K, but IOI could not be
calculated for this variable.

Introduction
Biological variability (BV) has important applications in laboratory medicine. It can
be a cause of variation in analyte values and provide guidance on reference interval
use. BV has three components: between-individual variation (CVg), caused by
differences in mean values of a particular analyte among members of a group, withinindividual variation (CVi), caused by fluctuations around an individual’s inherent
homeostatic set point, and analytical variation (CVa).1 Although BV data are commonly
investigated in human medicine, they are less emphasized in veterinary species.
The optimal method of results interpretation of TEG data is not clear. While
population-based reference intervals (PRI) are used for many analytes, reference
change values (RCV) are more sensitive for disease detection for other analytes. The
relative sensitivity of PRI or RCV in detecting significant deviations of reported analyte
values can be derived from BV data, via incorporation of CVi and CVg can into a simple
formula to calculate index of individuality (IOI). This section of the thesis reports
measured BV of the four TEG parameters R, K, angle and MA, and calculated IOI, in
clinically healthy horses.
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Materials and Methods
Animals and sample handling
This prospective study was conducted over a five week period using ten healthy
horses randomly pulled from a research and teaching herd. Animal use and sampling
of blood was approved by the Institutional Animal Care and Use Committee of The
University of Tennessee (protocol number 2097-0612). Horses ranged in age from 8-15
years, were mares, and included two Quarter horses, two Tennessee Walking Horses,
one Missouri Fox Trotter, and five mixed breed horses. Horses were housed on pasture
with free access to water and were fed free choice, mixed grass hay daily. Animal
health was assessed one week prior to beginning the study using physical examination
by a board-certified large animal internist (KM) and routine laboratory evaluation
consisting of a CBC (including platelet count; ADVIA 120, Bayer HealthCare LLC,
Tarrytown, NY ), biochemical testing (Cobas c 501, Roche Diagnostics, Indianapolis,
IN), and coagulation analysis (STA Compact, Diagnostica Stago, Parsippany, NJ).
Blood smear review accompanied each CBC. Coagulation analysis consisted of
prothrombin time, partial thromboplastin time, and fibrinogen concentration. Inclusion
criteria required horses to have an unremarkable physical examination and medical
history, laboratory values that were within institutional equine reference intervals, and
no medication administration in the previous two weeks. Medications were not
administered during the course of the study.
Horses were stall-confined overnight and fasted for approximately ten hours prior
to each blood sampling event; blood was collected from each horse once weekly for five
weeks by two large animal internists. To minimize pre-analytical variation, all samples
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were taken between 7:00 and 11:00 a.m. and were obtained from a jugular vein directly
into a 3.2% citrated vacutainer tube (BD Vacutainer Evacuated Citrate Tube, Vacutainer
Holder, and Precision Glide needles, Becton, Dickinson, and Company, Franklin Lakes,
NJ) using a vacuum collection system and 1.5" 20 g needle.2,3 The jugular vein used
was alternated each week. Blood samples were maintained at room temperature for
approximately 30 minutes from the time of collection to the start of the TEG assay (TEG
5000, Haemoscope Corporation, Niles, IL) to mitigate variations in results due to
different storage times.4,5

Thromboelastography
A tissue factor (TF)-activated TEG assay performed at 37C was used throughout
the study. TF (Innovin, Dade-Behring, Marburg, Germany) was diluted using
phosphate-buffered saline (PBS; PBS powder, pH 7.4, Sigma-Aldrich, St. Louis, MO )
and bovine serum albumin (BSA; BSA 30% solution, Sigma-Aldrich, St. Louis, MO)
according to previously published protocols.6 Weight of material in the TF vial is
considered proprietary information, and the exact TF dilution achieved by reconstituting
the 10 mL Innovin vial using 2.0 mL sterile, deionized water could not be calculated. If
the dilution used is considered 1:2 (w/v), and the subsequent dilution created by adding
an aliquot of the prepared Innovin to the BSA/PBS solution considered 1:50, the final
dilution is estimated to be 1:100. TF target concentration in the TEG sample cup was
1:3600. Based on a study in our laboratory (see Chapter 2) and consultation with other
investigators (personal communication: Catherine R. Wagg, Faculty of Veterinary
Medicine, University of Calgary, Calgary, Canada, 2011 and Roger C. Carroll, Graduate
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School of Medicine, University of Tennessee, Knoxville, TN, 2013), TF is stable for at
least six months when frozen at -70°C. Accordingly, TF was prepared prior to the start
of the study and aliquots stored at -70°C until use.
For each individual TEG assay, the reaction cup held 10 L of diluted TF (thawed to
room temperature immediately prior to use), 20 uL of 0.2 M CaCl2 (Haemonetics
Corporation, Niles, IL) and 330 L of citrate-anticoagulated whole blood. TF and
calcium solutions were added to the reaction cup first, and whole blood was added
when the temperature of the cup returned to 37°C. Contents of the reaction cup were
immediately and gently mixed using re-aspiration into the pipette tip to ensure adequate
mixing of all components before each TEG assay was started.7 All samples were run in
duplicate.
Machine balance and e-test were assessed daily prior to sample analysis, according
to manufacturer instructions. TEG analytical performance was monitored daily, using
two-level (normal and abnormal) quality control materials (Level I Control and Level II
Control, respectively, Haemonetics Corporation, Braintree, MA) run in duplicate.
Control data were considered acceptable if results fell within manufacturer-provided
ranges for each control material. All data were collected electronically using instrument
software (TEG Analytical Software Version 4.2, Haemoscope Corporation, Braintree,
MA). To minimize pre-analytical and analytical variation, all TEG assays (including
control runs) were performed by one individual (JLS), and all reagents and supplies
used during the course of the study were from one lot number, respectively.

26

Statistical Analysis
Statistical analyses were conducted using computer software (SAS Institute Inc.,
Version 9.3 SAS for Windows, Cary, NC) and an approach for biological variation
suggested by Fraser and Harris.3,8 The data were screened for outliers, first using the
Cochran’s C test to identify outliers in the duplicate results and then in the variance of
subject means. Values for R and K from one horse obtained during week 3 were
excluded as a result of this analysis. Reed’s criterion was then used to identify
individuals with overall mean values for R, K, angle and MA that differed from all other
subject’s means. Values for MA from one horse were subsequently excluded from
further analysis. Between-horse variance, within-horse variance, and analytical
variance were then obtained for each measurement using a nested ANOVA. Variances
and the overall mean for each measurement were used to calculate the corresponding
coefficients of variation, CVi, CVg and CVa. Values of P < 0.05 were considered
significant for all statistical tests.
The index of individuality (IOI) was calculated using the formula
√

where CVi is within-horse variation, CVg is between-horse variation and CVa is
analytical variation.
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Results
Study population
All horses used in the study were healthy on physical examination and had
hematologic, biochemical, and coagulation parameters that were within institutional
equine reference intervals (data not shown).

Biologic Variation and IOI of TEG variables
CVi (%) for TEG variables R, K, Angle and MA are 26.8, 31.0, 9.4 and 3.4,
respectively. CVg (%) for R, K, Angle and MA are 5.2, 0.0, 6.2 and 4.1, respectively.
CVa (%) for R, K, Angle and MA are 5.9, 5.9, 21.7, 4.4, respectively. Calculated IOI for
R, K, Angle and MA are 5.3, not assessed, 3.8 and 1.4, respectively (see Table 1).
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Table 1: Biological variation data and IOI of four TEG variables in 10 healthy horses.

TEG variable

CVi (%)

CVg (%)

CVa (%)

IOI

Total # samples

R

26.8

5.2

5.9

5.3

47

K

31.0

0.0

5.9

NA

47

Angle

9.4

6.2

21.7

3.8

48

MA

3.4

4.1

4.4

1.4

43

Table 1. Summary of CVi, CVg, CVa and calculated IOI. The total number of samples
is the number collected from all horses over the course of the experiment after removing
outliers. NA – not assessed
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Discussion
Biological variation estimates in people are made in clinically healthy individuals,
even though resulting data are intended to be applied to all populations (sick, adult,
geriatric, etc.).1,3,8-10 Although mean values for laboratory results can vary by sex,
health status, breed, and age, the inherent biological variability around a given
homeostatic set point appears constant, even in chronic disease states. 11-15 This
suggests that BV data from our study are likely applicable to most horses, not just
healthy, non-athletic mares.
Studies in humans indicate biological variation does not change significantly in
disease; however, most data concerning non-healthy individuals were obtained from
patients with chronic, stable diseases, not acute disease or emergent conditions. It
seems plausible that, in acute disease, acute decompensation of chronic disease, or
during times of growth and development (i.e., when measured homeostatic set points
may be in flux), that BV may be greater than it is in steady states (health or chronic,
stable disease). There is no prior published information regarding biological variation of
TEG variables in horses in either health or disease, so it is not clear how or if BV might
change in different homeostatic or pathologic conditions in horses. It is important to
remember, particularly in the context of viscoelastic coagulation analysis, that changes
in hematological variables influence patient data. For example, studies investigating
effects of erythrocyte mass on thromboelastometry (ROTEM™) have shown that there
is an inverse relationship between hematocrit and coagulability. Tracings appear
hypocoagulable as hematocrit increases and hypercoagulable as hematocrit
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decreases.16,17 Erythrocyte and platelet mass changes occur in many critical care
patients and have potential to affect results of viscoelastic testing.
Index of individuality (IOI) is a unitless index derived from a calculation using CVa,
CVi and CVg. By convention, when the resulting number is greater than 1.4,
population-based reference intervals are considered acceptable for clinical
interpretation. When IOI is less than 0.6, use of RCV to interpret patient data is
considered optimal. Results from this study suggest that R, K and angle data can be
appropriately interpreted using PRIs. IOI for MA was exactly 1.4; PRIs are likely
appropriate for this variable as well, but a small, clinically significant change may not be
as easily detected as if IOI were greater. IOI for K is listed as NA (see Table 1). This is
because the variation attributable to K’s CVg was zero, and CVg is in the denominator
of the IOI formula; a number divided by zero is indeterminate. If CVg were very small
(approaching zero but with a numeric value), the resulting IOI would be much greater
than 1.4.
CVa was highest for angle (21.7 % vs. all other values less than 6.0%). The exact
reason for this is not clear. It is possible that TF-activated TEG is not the optimal way to
measure this particular variable, and that another method may increase precision. Our
controls were within limits for all variables, suggesting analytical error did not contribute
to the variation in angle. Additionally, CV calculated using quality control material (QCM
I) for angle was less than 0.4%, perhaps suggesting whole horse blood has components
or matrix effects that caused the relatively high CVa associated with angle
measurement. The addition of TF has been reported to decrease analytical variability in
TEG results.18 It could be that increasing TF concentration beyond that used here may
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decrease angle variability. A consequence of the high CVa for angle is that the degree
of analytical variation may make it difficult to identify small, medically significant,
changes in that variable.
Fraser and Harris and others advocate the ideal biological variation study would
involve all samples being collected and then stored under conditions ensuring sample
stability until one large analytical run can be performed.3,10 This design is favored
because it mitigates the effect of between-run analytical variation on results. Due to
the inherent sample instability associated with whole blood TEG assays and an inability
to freeze whole blood intended for TEG analysis, a limitation of this study is that we
analyzed samples in different runs, 30 minutes after collecting the blood. 4,5,19 Although
not the ideal approach, this experimental design is often used in instances where
sample instability precludes long term storage 8,3 An advantage of our design is that it
mirrors how TEG is performed in many routine clinical situations.
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Chapter IV: Conclusions

The first part of this thesis provides information regarding stability of a key TEG
assay component, tissue factor. The data indicated tissue factor can be frozen at
-70°C for at least 6 months. Accordingly, a large batch of TF was prepared and
aliquots frozen for the subsequent biological variation study. The second part of this
document describes biological variation and analytical variation for the TF-activated
TEG variables, R, K, angle and MA, in healthy horses. Incorporation of the BV and CVa
data into the index of individuality formula demonstrates that population-based
reference intervals are an appropriate way to interpret TF-activated TEG data from
individual horses.
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